Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Puma Biotechnology stock | $9.08

Own Puma Biotechnology stock in just a few minutes.


Fact checked

Puma Biotechnology, Inc is a biotechnology business based in the US. Puma Biotechnology shares (PBYI) are listed on the NASDAQ and all prices are listed in US Dollars. Puma Biotechnology employs 269 staff and has a trailing 12-month revenue of around USD$235.5 million.

How to buy shares in Puma Biotechnology

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Puma Biotechnology. Find the stock by name or ticker symbol: PBYI. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Puma Biotechnology reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$9.08, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Puma Biotechnology, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Puma Biotechnology. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Puma Biotechnology share price

Use our graph to track the performance of PBYI stocks over time.

Puma Biotechnology shares at a glance

Information last updated 2020-11-30.
Latest market closeUSD$9.08
52-week rangeUSD$5.5 - USD$14.95
50-day moving average USD$9.4379
200-day moving average USD$10.1869
Wall St. target priceUSD$10.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.41

Buy Puma Biotechnology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Puma Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Puma Biotechnology price performance over time

Historical closes compared with the close of $9.08 from 2020-11-16

1 week (2021-01-07) -18.57%
1 month (2020-12-16) -18.05%
3 months (2020-10-16) -7.54%
6 months (2020-07-16) -7.06%
1 year (2020-01-16) 2.08%
2 years (2019-01-16) -64.15%
3 years (2018-01-16) 90.85
5 years (2016-01-15) 49.82

Is Puma Biotechnology under- or over-valued?

Valuing Puma Biotechnology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Puma Biotechnology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Puma Biotechnology's PEG ratio

Puma Biotechnology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.03. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Puma Biotechnology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Puma Biotechnology financials

Revenue TTM USD$235.5 million
Gross profit TTM USD$235.4 million
Return on assets TTM -6.78%
Return on equity TTM -671.97%
Profit margin -23.87%
Book value $0.591
Market capitalisation USD$452.1 million

TTM: trailing 12 months

Shorting Puma Biotechnology shares

There are currently 8.1 million Puma Biotechnology shares held short by investors – that's known as Puma Biotechnology's "short interest". This figure is 1% up from 8.0 million last month.

There are a few different ways that this level of interest in shorting Puma Biotechnology shares can be evaluated.

Puma Biotechnology's "short interest ratio" (SIR)

Puma Biotechnology's "short interest ratio" (SIR) is the quantity of Puma Biotechnology shares currently shorted divided by the average quantity of Puma Biotechnology shares traded daily (recently around 550681.39059305). Puma Biotechnology's SIR currently stands at 14.67. In other words for every 100,000 Puma Biotechnology shares traded daily on the market, roughly 14670 shares are currently held short.

However Puma Biotechnology's short interest can also be evaluated against the total number of Puma Biotechnology shares, or, against the total number of tradable Puma Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Puma Biotechnology's short interest could be expressed as 0.2% of the outstanding shares (for every 100,000 Puma Biotechnology shares in existence, roughly 200 shares are currently held short) or 0.2644% of the tradable shares (for every 100,000 tradable Puma Biotechnology shares, roughly 264 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Puma Biotechnology.

Find out more about how you can short Puma Biotechnology stock.

Puma Biotechnology share dividends

We're not expecting Puma Biotechnology to pay a dividend over the next 12 months.

Puma Biotechnology share price volatility

Over the last 12 months, Puma Biotechnology's shares have ranged in value from as little as $5.5 up to $14.95. A popular way to gauge a stock's volatility is its "beta".

PBYI.US volatility(beta: 1.19)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Puma Biotechnology's is 1.1917. This would suggest that Puma Biotechnology's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Puma Biotechnology overview

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. The company was founded in 2010 and is headquartered in Los Angeles, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site